Key Quantitative Figures

  • Amount Raised through Preferential Issue: ₹4,411.73 lakh
  • Date of Fund Raising: 18th March 2026
  • Funds Utilized against Original Objects:
  • Capital Expenditure for API Manufacturing: Original allocation ₹1,100.00 lakh; Funds utilized ₹796.31 lakh
  • Working Capital Requirement: Original allocation ₹1,711.73 lakh; Funds utilized ₹0.00 lakh
  • Repayment of unsecured loans to promoters/Directors: Original allocation ₹1,600.00 lakh; Funds utilized ₹400.00 lakh
  • Amount of Deviation/Variation for the quarter: ₹0.00 lakh across all objects

Dates of Action

  • Quarter Ended: 30th September 2026
  • Audit Committee and Board Review Date: 11th November 2026
  • Date of Submission to BSE: 11th November 2026

Parties Involved

  • Regulator: BSE Limited
  • Signatories:
  • Mukund Kakani, Managing Director (signed the statement)
  • Venkatesh Achanta, Company Secretary & Compliance Officer (signed the submission letter)

Purpose and Rationale

The disclosure is a regulatory requirement to report on the utilization of funds raised through a preferential issue. The company confirms that there has been no deviation or variation from the objects stated in the explanatory statement to the notice of the Extra-Ordinary General Meeting.

Financial and Operational Impact

The company confirms no deviation in fund utilization. The funds are being used exactly as per the original objects approved by shareholders:

  • Capital expenditure for manufacturing Active Pharmaceutical Ingredients and intermediates, specialty chemicals in therapeutic categories including Anti-HIV and CNS segments.
  • Specific capex includes civil construction, procurement and installation of equipment, and augmentation of electrical infrastructure.
  • Partial repayment of unsecured loans to promoters/directors.
  • No funds have been utilized for working capital requirements as of this quarter.

Monitoring and Approval

  • Monitoring Agency: Not applicable
  • Audit Committee Comments: Nil
  • Auditor Comments: Nil
  • Shareholder Approval for Change: Not required as there is no deviation

Capital Structure Impact

The disclosure pertains to the utilization of funds already raised through a preferential issue on 18th March 2026. No new capital structure changes are reported in this filing.

Signature and Authentication

The submission letter was digitally signed by Company Secretary & Compliance Officer Achanta Venkatesh on 11th November 2026 at 17:42:25 IST. The statement was signed by Managing Director Mukund Kakani in Secunderabad on 11th November 2026.

#Tags: #GodavariDrugs #SEBIReg32 #FundUtilization #RegulatoryCompliance #NoDeviation